Recent Updates
Recently added Catalysts

denosumab

Phase 3

Osteoporosis, Postmenopausal | Small molecule | Endocrine |GSK plc|Last Updated: Oct 31, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials3
Total Enrollment871
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02014467Denosumab China Phase III StudyPHASE3 COMPLETED 486Jan 1, 2014Aug 1, 2015Oct 31, 20168 China
NCT01495000A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of DenosumabPHASE3 COMPLETED 250Jan 1, 2012Feb 1, 2013Feb 7, 201411 India
NCT01457950A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of DenosumabPHASE3 COMPLETED 135Nov 1, 2011Jun 1, 2013May 7, 201410 South Korea
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12
Baseline and Month 12

Bone mineral density (BMD) is the amount of bone mineral in bone tissue. BMD scan was done using dual energy x-ray absorptiometry (DXA). It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calcuated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. The analysis was performed by Analysis of Covariance (ANCOVA) model adjusted for treatment, region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as Baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the Last Observation Carried Forward (LOCF), provided the assessment was taken on or after at least one month on-therapy.

Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6
Baseline and Month 6

Bone mineral density (BMD) at the lumbar spine was measured by the dual-energy x-ray absorptiometry (DXA) scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an Analysis of Covariance (ANCOVA) model with terms for treatment and baseline BMD at the lumbar spine (as a continuous covariate).

Mean Percent Change From Baseline in Lumbar Spine BMD at Month 6
Baseline and Month 6

Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using the Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 6 - measure at Baseline) divided by the measure at Baseline \* 100.

Secondary Endpoints
Percent Change From Baseline in BMD at the Lumbar Spine at Month 6
Baseline and Month 6
Percent Change From Baseline in BMD at the Total Hip at Month 6
Baseline and Month 6
Percent Change From Baseline in BMD at the Femoral Neck at Month 6
Baseline and Month 6
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Denosumab 60mgEXPERIMENTALinjection
PlaceboPLACEBO_COMPARATORinjection
Arm 1EXPERIMENTALdenosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment
Arm 2PLACEBO_COMPARATORplacebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment
Arm 3EXPERIMENTALopen-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase
Interventions
NameTypeDescription
DenosumabDRUGInjection
PlaceboDRUGInjection
Elemental CalciumDIETARY_SUPPLEMENTOral, at least 600 mg
Vitamin DDIETARY_SUPPLEMENTOral, at least 400 IU
open-label denosumabDRUGopen-label phase: 60mg subcutaneous injection, single dose
Unlock Study Design Details
Eligibility Criteria
Age Range60 Years — 90 Years
SexFEMALE
Healthy VolunteersNo
Study Sites8

Inclusion Criteria: * Subject is willing and able to provide written informed consent. * Of Chinese origin - defined as being born in China, having four ethnic Chinese grandparents. * Ambulatory woman between the age of 60 and 90 years, inclusive. * The subject has a BMD absolute value consistent w...

Countries:ChinaIndiaSouth Korea
Unlock Eligibility Criteria